seekingalpha.com/article/...nings-call-transcript?part=single
Mit Aussagen zu Bremelanotide und Palatin Technologies, zum Beispiel:
" For Bremelanotide, we made good progress in the quarter, continuing to advance our ongoing development work with our partner Palatin for the planned NDA submission in early 2018. And we strengthened our financial position. We generated strong revenues and profitability in the second quarter, combined with some balance sheet adjustments, extending maturities, and reducing our overall debt balance which allowed us to end the quarter with nearly $400 million in cash and investments. All in all, a fantastic quarter both financially and operationally."
etc etc